• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者对参与癌症化学预防试验的看法。

Patients' perceptions on participation in a cancer chemoprevention trial.

作者信息

Tangrea J A, Adrianza M E, Helsel W E

机构信息

Cancer Prevention Studies Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892.

出版信息

Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):325-30.

PMID:1303133
Abstract

The perceptions of patients regarding the benefits, disadvantages, and importance of their participation in a long-term cancer chemoprevention trial, the Isotretinoin-Basal Cell Carcinoma Prevention Trial, were assessed through a questionnaire mailed at the conclusion of the 3-year treatment period of the trial. Responses were evaluated overall, as well as within subgroups defined by sex, age, education level, treatment group, presence of side effects, and the number of skin biopsies performed during the 3-year intervention phase. Overall, "careful medical follow-up received" (43%) and "being part of a research effort" (24%) were the most frequently cited important benefits, while the "amount of time taken to attend clinic" (32%) and "side effects" (20%) were the most frequently cited unpleasant aspects of trial participation. Most surveyed patients viewed the study as "very or extremely important" to their general health (62%) and their skin cancer condition (88%) and, as a result of participation, felt "much or somewhat better" physically (52%). The majority indicated that they would "definitely or probably" be willing to take part in another research study (79%) and take the study medication, if it were shown to be effective in the trial (78%). Overall and subgroup data provide important insights into patient motivations and attitudes regarding cancer chemoprevention trial participation, adherence, and satisfaction.

摘要

通过在一项长期癌症化学预防试验(异维甲酸 - 基底细胞癌预防试验)的3年治疗期结束时邮寄的问卷,评估了患者对参与该试验的益处、弊端及重要性的看法。对总体回答以及按性别、年龄、教育水平、治疗组、是否有副作用以及在3年干预阶段进行的皮肤活检数量定义的亚组回答进行了评估。总体而言,“接受仔细的医学随访”(43%)和“参与一项研究工作”(24%)是最常被提及的重要益处,而“去诊所就诊花费的时间”(32%)和“副作用”(20%)是参与试验最常被提及的不愉快方面。大多数接受调查的患者认为该研究对他们的总体健康状况“非常或极其重要”(62%)以及对他们的皮肤癌病情“非常或极其重要”(88%),并且由于参与试验,他们感觉身体“好多了或有所改善”(52%)。大多数人表示,如果该研究药物在试验中被证明有效,他们“肯定或很可能”愿意参加另一项研究(79%)并服用该研究药物(78%)。总体和亚组数据为患者参与癌症化学预防试验的动机、依从性和满意度提供了重要见解。

相似文献

1
Patients' perceptions on participation in a cancer chemoprevention trial.患者对参与癌症化学预防试验的看法。
Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):325-30.
2
Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. The Isotretinoin-Basal Cell Carcinomas Study Group.长期低剂量异维甲酸相关的临床和实验室不良反应:发生率及危险因素。异维甲酸-基底细胞癌研究组
Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):375-80.
3
Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.视黄醇与异维甲酸预防皮肤癌的试验:一项随机、双盲、对照试验。西南皮肤癌预防研究组
Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):957-61.
4
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.吸烟状况、疾病分期和原发肿瘤部位对头颈部维甲酸化学预防试验中第二原发性肿瘤发生率和肿瘤复发的影响。
Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):823-9.
5
Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin.隐性营养不良性大疱性表皮松解症中鳞状细胞癌的化学预防:系统性异维A酸1期试验结果
J Am Acad Dermatol. 2004 Apr;50(4):563-71. doi: 10.1016/j.jaad.2003.08.008.
6
Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial.皮肤基底细胞癌的反复发生与多因素生存分析:楠伯皮肤癌预防试验的随访数据
Am J Epidemiol. 2005 Apr 15;161(8):748-54. doi: 10.1093/aje/kwi098.
7
Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.前瞻性、随机、多中心、双盲安慰剂对照试验:比较辅助性干扰素α联合异维A酸与单用干扰素α治疗IIA期和IIB期黑色素瘤的疗效——欧洲黑色素瘤辅助治疗协作研究组
J Clin Oncol. 2005 Dec 1;23(34):8655-63. doi: 10.1200/JCO.2004.00.8128. Epub 2005 Oct 31.
8
Chemoprevention of head and neck cancer with retinoids: a negative result.维甲酸对头颈部癌症的化学预防:一项阴性结果。
Arch Otolaryngol Head Neck Surg. 2005 Mar;131(3):198-203. doi: 10.1001/archotol.131.3.198.
9
Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.在随机VATTC试验中血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与预防角质形成细胞癌的关联
J Natl Cancer Inst. 2008 Sep 3;100(17):1223-32. doi: 10.1093/jnci/djn262. Epub 2008 Aug 26.
10
Patients' perceptions on participation in a cancer chemoprevention trial.
Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(3):325-30.

引用本文的文献

1
Was it Worth It? Response Data from >650 United States and International Participants in Chemoprevention Trials.这值得吗?来自650多名美国和国际化学预防试验参与者的回应数据。
Cancer Prev Res (Phila). 2025 Sep 3. doi: 10.1158/1940-6207.CAPR-25-0180.
2
How can we support research participants who stop taking part? Communications guidance developed through public-researcher collaboration.我们如何支持那些停止参与研究的参与者?通过公众与研究者合作制定的沟通指南。
Res Involv Engagem. 2024 Apr 18;10(1):39. doi: 10.1186/s40900-024-00572-4.
3
Trials need participants but not their feedback? A scoping review of published papers on the measurement of participant experience of taking part in clinical trials.
试验需要参与者,但不需要他们的反馈?对已发表的关于测量临床试验参与者体验的文献进行的范围综述。
Trials. 2019 Jun 24;20(1):381. doi: 10.1186/s13063-019-3444-y.
4
Assessment of clinical trial participant patient satisfaction: a call to action.评估临床试验参与者的患者满意度:行动呼吁。
Trials. 2016 Oct 6;17(1):483. doi: 10.1186/s13063-016-1616-6.
5
Recruiting underserved populations to dermatologic research: a systematic review.招募服务不足人群参与皮肤科研究:系统评价。
Int J Dermatol. 2011 Apr;50(4):385-95. doi: 10.1111/j.1365-4632.2010.04813.x.
6
The Tuskegee Legacy Project: history, preliminary scientific findings, and unanticipated societal benefits.塔斯基吉遗产项目:历史、初步科学发现及意外的社会效益。
Dent Clin North Am. 2003 Jan;47(1):1-19. doi: 10.1016/s0011-8532(02)00049-6.
7
Attitudes and beliefs of African Americans toward participation in medical research.非裔美国人对参与医学研究的态度和信念。
J Gen Intern Med. 1999 Sep;14(9):537-46. doi: 10.1046/j.1525-1497.1999.07048.x.